EUVIMEDEUVIMED entdecken
Crossref

Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy

Bao-Toan Nguyen Dang, Ramesh Duwa, Sooyeun Lee, Taeg Kyu Kwon, Jae-Hoon Chang, Jee-Heon Jeong, Simmyung Yook

Journal of Controlled Release · 2024-08 · 372 · 587-608

DOI: 10.1016/j.jconrel.2024.06.062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-08. Verfasst von Bao-Toan Nguyen Dang und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea; Department of Precision Medicine, School of Medicine, Sungkyunkwan Universi…. Hauptthemen laut MEDLINE: Imidazoles, Toll-Like Receptor 8, Immunotherapy, Toll-Like Receptor 7. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-associated macrophages (TAMs) constitute 50-80% of stromal cells in most solid tumors with high mortality and poor prognosis. Tumor-infiltrating dendritic cells (TIDCs) and TAMs are key components mediating immune responses within the tumor microenvironment (TME). Considering their refractory properties, simultaneous remodeling of TAMs and TIDCs is a potential strategy of boosting tumor immunity and restoring immunosurveillance. In this study, mannose-decorated poly(lactic-co-glycolic acid) nanoparticles loading with R848 (Man-pD-PLGA-NP@R848) were prepared to dually target TAMs and TIDCs for efficient tumor immunotherapy. The three-dimensional (3D) cell culture model can simulate tumor growth as influenced by the TME and its 3D structural arrangement. Consequently, cancer spheroids enriched with tumor-associated macrophages (TAMs) were fabricated to assess the therapeutic effectiveness of Man-pD-PLGA-NP@R848. In the TME, Man-pD-PLGA-NP@R848 targeted both TAMs and TIDCs in a mannose receptor-mediated manner. Subsequently, Man-pD-PLGA-NP@R848 released R848 to activate Toll-like receptors 7 and 8, following dual-reprograming of TIDCs and TAMs. Man-pD-PLGA-NP@R848 could uniquely reprogram TAMs into antitumoral phenotypes, decrease angiogenesis, reprogram the immunosuppressive TME from "cold tumor" into "hot tumor", with high CD4+ and CD8+ T cell infiltration, and consequently hinder tumor development in B16F10 tumor-bearing mice. Therefore, dual-reprograming of TIDCs and TAMs with the Man-pD-PLGA-NP@R848 is a promising cancer immunotherapy strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesToll-Like Receptor 8ImmunotherapyToll-Like Receptor 7Tumor-Associated MacrophagesMannoseMice, Inbred C57BLPolylactic Acid-Polyglycolic Acid CopolymerNanoparticlesAnimalsTumor MicroenvironmentDendritic CellsCell Line, TumorMiceNeoplasmsFemaleHumansMembrane Glycoproteins

Stichwörter der Autor:innen

Cancer immunotherapyHot tumorMannose receptorNanoparticlesSpheroidTumor-associated macrophages

Substanzen

ImidazolesToll-Like Receptor 8resiquimodToll-Like Receptor 7MannosePolylactic Acid-Polyglycolic Acid CopolymerTlr7 protein, mouseTLR8 protein, mouseMembrane Glycoproteins

Autor:innen und Institutionen

  • College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea; Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea.
  • Department of Biopharmaceutical Convergence, Sungkyunkwan University, Suwon 16419, Republic of Korea; Department of Radiology, Molecular Imaging Program at Stanford (MIPS), School of Medicine, Stanford University, Stanf…
  • College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea.
  • Department of Immunology, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
  • College of Pharmacy, Yeungnam University, Gyeongbuk 38541, Republic of Korea.
  • Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon 16419, Republic of Korea. Electronic address: jeeheon@skku.edu.

Zitieren

APA

Dang, B. N., Duwa, R., Lee, S., Kwon, T. K., Chang, J. H., Jeong, J. H., & Yook, S. (2024). Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy. Journal of Controlled Release, 372, 587-608. https://doi.org/10.1016/j.jconrel.2024.06.062

Vancouver

Dang BN, Duwa R, Lee S, Kwon TK, Chang JH, Jeong JH, et al. Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy. Journal of Controlled Release. 2024;372:587-608. doi:10.1016/j.jconrel.2024.06.062

BibTeX
@article{Dang2024,
  author = {Dang, Bao-Toan Nguyen and Duwa, Ramesh and Lee, Sooyeun and Kwon, Taeg Kyu and Chang, Jae-Hoon and Jeong, Jee-Heon and Yook, Simmyung},
  title = {Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy},
  journal = {Journal of Controlled Release},
  year = {2024},
  volume = {372},
  pages = {587--608},
  doi = {10.1016/j.jconrel.2024.06.062}
}
Kostenlos starten →